307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study

• Ralf Gutzmer,
• Caroline Robert,
• Gabriella Liszkay,
• Grant McArthur,
• Jacek Mackiewicz,
• Rodrigo Munhoz,
• Paolo Ascierto,
• Judit Olah,
• Paola Queirolo,
• Luis De La Cruz Marino,
• Kalpit Shah,
• Harper Forbes,
• Christian Hertig,
• Yibing Yan

Affiliations

Ralf Gutzmer

17 Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany

Caroline Robert

4 Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France

Gabriella Liszkay

Aff2 grid.419617.c0000000106678064OncodermatologyNational Institute of Oncology Budapest Hungary

Grant McArthur

Aff2 grid.1055.10000000403978434Peter MacCallum Cancer Centre East Melbourne Australia

Jacek Mackiewicz

Aff1 0000 0001 2205 0971grid.22254.33Chair of Medical BiotechnologyUniversity of Medical Sciences 15 Garbary street 61-866 Poznan Poland

Rodrigo Munhoz

Oncology Center, Hospital Sírio-Libanês, São Paulo, São Paulo, Brazil

Paolo Ascierto

6Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy

Judit Olah

13Szegedi Tudomanyegyetem Szent-Gyorgyi, Szeged, Hungary

Paola Queirolo

9 Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Luis De La Cruz Marino

6Hospital Universitario Virgen Macarena, Seville, Spain

Kalpit Shah

10Genentech, Inc., South San Francisco, CA, USA

Harper Forbes

11F. Hoffmann-La Roche Ltd., Mississauga, Canada

Christian Hertig

11F. Hoffmann-La Roche Ltd., Mississauga, Canada

Yibing Yan

10Genentech, Inc., South San Francisco, CA, USA